Metsera, Inc. (MTSR)
Nov 13, 2025 MTSR was delisted (reason: acquired by PFE)
70.50
-0.25 (-0.35%)
Inactive · Last trade price
on Nov 13, 2025
Company Description
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases.
It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain.
The company was incorporated in 2022 and is based in New York, New York.
Metsera, Inc.
| Country | United States |
| Founded | 2022 |
| IPO Date | Jan 31, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 81 |
| CEO | Christopher Bernard |
Contact Details
Address: 3 World Trade Center, 175 Greenwich Street New York, New York 10007 United States | |
| Phone | 212 784 6595 |
| Website | metsera.com |
Stock Details
| Ticker Symbol | MTSR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0002040807 |
| CUSIP Number | 59267L107 |
| ISIN Number | US59267L1070 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christopher Whitten Bernard | Co-Founder, President, Chief Executive Officer and Director |
| Dr. Clive A. Meanwell M.D., Ph.D. | Co-Founder and Executive Chairman |
| Christopher J. Visioli | Co-Founder, Chief Financial Officer and Chief Business Officer |
| Paul L. Berns | Co-Founder and Lead Independent Director |
| Dr. Brian Hubbard Ph.D. | Chief Scientific Officer |
| Dr. Gbolahan Amusa Benz C.F.A., M.D. | Executive Vice President of Strategic Finance and Investor Relations |
| Melissa Enbar | Chief Human Resources Officer |
| Nancye Green | Chief Experience Officer |
| Michael Donovan | Chief Design Officer |
| Dr. Steven Marso M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2025 | SCHEDULE 13D/A | Filing |
| Nov 14, 2025 | SCHEDULE 13G | Filing |
| Nov 13, 2025 | SCHEDULE 13G/A | Filing |
| Nov 13, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Nov 13, 2025 | 8-K | Current Report |
| Nov 13, 2025 | 25-NSE | Filing |
| Nov 12, 2025 | 10-Q | Quarterly Report |
| Nov 10, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 10, 2025 | 8-K | Current Report |
| Nov 6, 2025 | 8-K | Current Report |